[The use of Ukrainian laferon in the combined treatment of patients with chronic myeloid leukemia].

Abstract

A study was made into the effect of laferon on effectiveness of treatment of patients with chronic myeloid leukemia (CML). The authors have reached the conclusion that drug tolerance in the patients is fairly good. The number of negative reactions within a few days of the start of laferon therapy did not exceed the level reported from other countries. Small series and short-term follow-up does not allow judgement about effects of the drug on survival but one can say with certainty that the employment of laferon in the treatment programme for CML in different categories of risk permits achieving clinical and hematological compensation on more frequent occasions. The quality of the patients' life gets improved. Chemotherapy was found to lessen the risk for infectious and inflammatory complications.

• Authors: N M Tretiak, M V Bondar, A I Koval', I Iu Slavchenko, V M Mnyshenko, O M Vakul'chuk, A I Hordiienko
• Journal: Likars'ka sprava (Lik Sprava) Issue 5 Pg. 131-4 (Jul 1999) ISSN: 1019-5297 [Print] Ukraine
• Vernacular Title: Zastosuvannia vitchyznianoho laferonu u kompleksnomu likuvanni khvorykh na khronichnu miieloïdnu leĭkemiiu.
• PMID: 10822701 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Interferon Type I
• Recombinant Proteins

Topics

• Adolescent
• Adult
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Female
• Humans
• Interferon Type I (adverse effects, therapeutic use)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (blood, diagnosis, drug therapy)
• Male
• Middle Aged
• Recombinant Proteins
• Remission Induction
• Risk Factors
• Time Factors